←
CA: A Cancer Journal for Clinicians5,078 posts
CA: A Cancer Journal for Clinicians avatar✓

CA: A Cancer Journal for Clinicians ✓

@CACancerJournal

As the flagship journal of the American Cancer Society, CA publishes the latest cancer statistics, ACS guidelines, and reviews on the current state of cancer.

◷ Joined January 2009▧ 2,695 Photos and videos
Toni Choueiri, MD avatar
⟳ CA: A Cancer Journal for Clinicians retweeted
Toni Choueiri, MD@DrChoueiri·Nov 12

JUST IN: @AmericanCancer (ACS) updates their guidance about routine PSA screening for #prostatecancer, moving off "shared decision-making". This is a major shift since the last ACS recommendations in 2010: 1) High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69 2) Average risk: PSA every 2 years, ages 50–69. American Cancer Society 3) Non-Black men with 1 first-degree relative diagnosed ≥65: PSA every 2 years, ages 45–69. 4) Age 70–74: individualized decision; if screening continues, every 2 years. 5) Age ≥75: generally no screening; very healthy men 75–79 may discuss continued screening. 6) No screening ≥80 and no screening at any age with life expectancy <10 years. @CACancerJournal @DanaFarber_GU @harvardmed @OpenMedInsights Link: acsjournals.onlinelibrary.wi…

Post attachmentPost attachment
Adam B. Weiner, MD avatar
⟳ CA: A Cancer Journal for Clinicians retweeted
Adam B. Weiner, MD@Adam_Weiner535·Nov 12

🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨 @CACancerJournal 📋 Average risk: PSA every 2 yrs, ages 50-69 📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69 📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69 🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy 🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs ⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69 🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010 🔗 doi.org/10.3322/caac.70112 @UroOnc @urotoday @UrologyTimes @PCF_Science @AmerUrological

Post attachment